Urate Lowering Therapies and Left Ventricular Diastolic Dysfunction
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
Hyperuricemia is an additional risk factor for cardiovascular disease, associating with left
ventricular diastolic dysfunction in individuals with metabolic syndrome. The effect of
urate-lowering therapies on left ventricular diastolic dysfunction remains unclear. The study
is conducted to investigate whether febuxostat or benzbromarone might improve left
ventricular diastolic dysfunction in individuals with metabolic syndrome and hyperuricemia